Can Ethics Keep Pace with Pharma Innovation?

Is 75% a good enough diagnostics rate? How do we eliminate bias from clinical trials? How do we protect patient data?

These are all essential questions that will govern the way the pharma industry evolves its ethical framework in a modern world, where expectations for progress will be higher and the pace of innovation will be faster. After all, we only need to look at the Theranos case to see the risks that emerge when ambition stretches beyond reality.

For Klaus Moosmayer, Chief Ethics, Risk and Compliance Officer at Novartis, there is a central question at the heart of this debate – can we trust companies to use data in the right way?

Robust ethical practices and rigorous approaches to using data and AI models are essential if patients and partners to the pharma industry are to get behind new innovations and practices.

For Moosmayer, we must get this right if we are able to harness the power of data to improve decision-making and fuel innovation.

As he puts it in his episode of the Wolters Kluwer Pharma Unlimited podcast, when it comes to updating ethical standards at speed, the big debate will be how we use data and how the industry can structure this in a legal way to get the best out of research and development, while still protecting privacy rights.

Listen to the Pharma Unlimited Podcast series – a new series where host Bertrand Bodson goes under the microscope to examine some of the biggest issues facing the pharma sector.